ATTACHMENT H: JOURNAL INFORMATION PIECE FOR ONCOLOGISTS
Important Safety Information for Oncologists
About Malignancy Risk With ACTEMRA®

ACTEMRA® (tocilizumab) is an interleukin-6 (IL-6) receptor antagonist that has been approved by the Food and Drug Administration (FDA) for three indications:

- Adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs) with a recommended ACTEMRA dosing interval of every 4 weeks for intravenous (IV) or every other week or weekly for subcutaneous (SC) administration.

- Children 2 years of age and older with active Polyarticular Juvenile Idiopathic Arthritis (PJIA) with a recommended ACTEMRA® dosing interval of every 4 weeks for IV administration.

- Children 2 years of age and older with active Systemic Juvenile Idiopathic Arthritis (SJIA) with a recommended ACTEMRA® dosing interval of every 2 weeks for IV administration.

The safety and efficacy of ACTEMRA for conditions other than RA, PJIA and SJIA have not yet been established.

Oncologists should be aware of important safety information about ACTEMRA.

Malignancies were observed in clinical studies of ACTEMRA. The impact of treatment with ACTEMRA on the development of the malignancies is not known, but malignancy is a known risk of biological products that suppress the immune system. ACTEMRA is an immunosuppressant and may increase the risk of malignancies.

Reporting Adverse Events
If you are consulted to a see a patient with cancer at any time after receiving ACTEMRA therapy, it is important that you report the case, even if you do not think there is a causal relationship. The information that you, as an oncologist, provide about these events may inform therapy and monitoring decisions for future patients.

Reporting is easy and maintains patient confidentiality. Your patient’s name or contact information is not needed. HIPAA does not apply to this adverse event reporting. You can report your cases to Genentech or directly to the FDA:
- Genentech at 1-888-835-2555
- MedWatch (FDA safety information and adverse event reporting program) at 1-800-332-1088 or online at www.fda.gov/medwatch/report.htm

Please visit www.ACTEMRA.com for Prescribing Information and Medication Guide.